Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting its major protease in a non-competitive way
O Augusto Chaves, CQ Sacramento… - bioRxiv, 2021 - biorxiv.org
Anticoagulants are associated with clinical benefit against the 2019 coronavirus disease
(COVID-19), preventing COVID-19 associated coagulopathy. Blood coagulation factor Xa …
(COVID-19), preventing COVID-19 associated coagulopathy. Blood coagulation factor Xa …
Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way
OA Chaves, CQ Sacramento… - Journal of Molecular …, 2022 - academic.oup.com
The severe coronavirus disease 2019 (COVID-19) is associated with coagulopathy.
Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin inhibitors, and …
Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin inhibitors, and …
Apixaban following discharge in hospitalised adults with COVID-19: Preliminary results from a multicentre, open-label, randomised controlled platform clinical trial
Background The role of thromboprophylaxis in the post-acute phase of COVID-19 is
uncertain due to conflicting results from randomised controlled trials and observational …
uncertain due to conflicting results from randomised controlled trials and observational …
[HTML][HTML] FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B. 1.1. 7 variant
The ongoing coronavirus disease 2019 (COVID-19) pandemic is caused by infection with
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human natural defense …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human natural defense …
Safety and efficacy analysis of apixaban compared to heparins in hospitalized non-critically ill COVID-19 patients
D Appiah, NJ Quinn, EG Messing… - Hospital …, 2022 - journals.sagepub.com
Purpose: Heparin-based regimens are recommended for anticoagulation in hospitalized
patients with COVID-19 though a study reported similar mortality with apixaban in critically ill …
patients with COVID-19 though a study reported similar mortality with apixaban in critically ill …
[HTML][HTML] Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
K Papaj, P Spychalska, P Kapica, A Fischer, J Nowak… - Plos one, 2022 - journals.plos.org
Based on previous large-scale in silico screening several factor Xa inhibitors were proposed
to potentially inhibit SARS-CoV-2 Mpro. In addition to their known anticoagulants activity this …
to potentially inhibit SARS-CoV-2 Mpro. In addition to their known anticoagulants activity this …
[HTML][HTML] Safety and efficacy of apixaban for therapeutic anticoagulation in critically ill ICU patients with severe COVID-19 respiratory disease
E Wenzler, MH Engineer, M Yaqoob, ST Benken - TH open, 2020 - thieme-connect.com
Introduction Despite the use of unfractionated heparin (UFH) or low molecular weight
heparin (LMWH), rates of thromboembolic disease, and subsequent morbidity and mortality …
heparin (LMWH), rates of thromboembolic disease, and subsequent morbidity and mortality …
[HTML][HTML] When to use anticoagulation in COVID-19
M Moll, JM Connors - Thrombosis Research, 2021 - ncbi.nlm.nih.gov
Early in the COVID-19 pandemic, infection with SARS-CoV-2 was noted to be associated
with a coagulopathy [1] and high rates of VTE observed in ICU patients, leading many to …
with a coagulopathy [1] and high rates of VTE observed in ICU patients, leading many to …
[HTML][HTML] Non-vitamin K antagonist oral anticoagulants for COVID-19 thrombosis
AK Hamad - Journal of Acute Disease, 2022 - journals.lww.com
Thrombotic complications appear to be a major predictor of death in COVID-19 patients, and
multiple studies have shown that anticoagulants can help to improve the outcome. The Food …
multiple studies have shown that anticoagulants can help to improve the outcome. The Food …
[HTML][HTML] Does chronic treatment with oral anticoagulants ameliorate the clinical course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in …
J Harenberg, R Bauersachs… - Seminars in Thrombosis …, 2021 - thieme-connect.com
The risk of ischemic stroke in patients with nonvalvular atrial fibrillation (NVAF) increases
from 1.5% at 50 to 59 years of age to 23.5% at 80 to 89 years of age, 1 and this is reflected in …
from 1.5% at 50 to 59 years of age to 23.5% at 80 to 89 years of age, 1 and this is reflected in …